• Extension of mono to diaryl hydroxylamines illuminates activities as potent pan and dual inhibitors of IDO1, IDO2 and TDO.
Introduction
In mammals and other vertebrates, three enzymes, IDO1, IDO2 and TDO, catalyze the rate-limiting first step of tryptophan catabolism down the kynurenine pathway which accounts for ≥95% of tryptophan catabolism 1, 2 . Whereas TDO is a predominantly hepatic enzyme functioning to maintain tryptophan homeostasis, IDO1 is induced by inflammation, particularly by IFN, and can be found in lymphoid tissues and organs, along mucosal surfaces, and in the placenta and epididymis 3 . IDO2 has been less thoroughly investigated than the other two enzymes, but the available data indicate it has a more restricted expression than IDO1 3 . In cancer patients, IDO1 expression has been observed at varying levels and frequencies in most tumor types while TDO is strongly expressed in hepatocarcinoma, but also weakly in many other tumor types 3 Extensive preclinical evidence indicates that IDO1 inhibitors can relieve T cell suppression and enhance cancer therapeutic responses 4, 5 , including when combined with cytotoxic chemotherapy, radiotherapy or immune checkpoint therapy [6] [7] [8] [9] . Nevertheless, the failure of the IDO1-selective inhibitor epaccadostat to provide a benefit in combination with the immune checkpoint agent pembrolizumab in a recent phase III clinical trial 10 in melanoma patients highlights the continuing challenges to exploit the role IDO1 has in regulating the immune system.
While this trial has raised many questions 11 , attendant with its failure has been the growing recognition of the complex role and importance of the related dioxygenases, TDO and IDO2 4, 5 , which, like IDO1, also exert root functions in cancer inflammatory programming. It has become clear that IDO1 drives both neovascularization along with immunosuppression in tumors. 12, 13 TDO promotes immunosuppression, but also other processes that promote metastatic progression 3, 14-17 . IDO2 drives inflammation in autoimmune and cancer settings including pancreas cancer [18] [19] [20] . Combo or pan IDO1/TDO/IDO2 inhibitors will potentially offer metabolic adjuvants to illuminate key questions concerning the peculiar nature of chronic inflammatory states that sustain cancer 21 . As metabolic adjuvants, IDO1-selective inhibitors do not plumb the full potential of blunting Trp catabolism. Emerging evidence indicates that TDO and IDO2 are jointly activated with IDO1 in many tumors 3, [14] [15] [16] [17] 22 , arguing for independent as well as overlapping functions. Whereas IDO1 modulates T-cell inflamed states, IDO2 influences B-cell inflamed states critical for autoimmunity 20 as well as certain cancers like pancreatic cancer 23, 24 .
IDO2 targeting may pose an additional benefit in mitigating autoimmune side-effects of immune checkpoint therapy based on evidence of a role in autoimmune inflammation 20, 25 . Lastly, resistance to IDO1 blockade in preclinical models is associated with upregulated Trp catabolism down the kynurenine pathway by TDO or IDO2 12 . In the wake of these discoveries, the next logical step would be the development of dual or broad spectrum inhibitors of tryptophan catabolism to target IDO1, IDO2 and TDO.
Although a large number of IDO1 inhibitors have been communicated 26, 27 , there are significantly fewer TDO 22, [28] [29] [30] [31] [32] and IDO2 inhibitors [33] [34] [35] described in the literature. To the best of our knowledge, there is only one report of dual inhibition in the literature 31 , although a collection of patents have appeared [36] [37] [38] [39] . Our recent report of monoaryl hydroxylamine activity as an impressive, structurally simple IDO1 inhibitor 40 prompted us to explore this structural class of compounds further for combinatorial activity against IDO/TDO enzymes. Cognizant of the potential therapeutic benefits that might accrue from joint inhibition of IDO2 and TDO, we therefore screened more broadly for the effects of diaryl hydroxylamines on IDO2 and TDO as well as IDO1, to identify pan or selective inhibitors.
Based on literature defining two major pockets termed A and B in the active site of IDO1 26, [41] [42] [43] . The expansion of our previously reported monoaryl hydroxylamines to diaryl derivatives was conceived initially as an effort to exploit both pockets in IDO1 to achieve more potent and selective inhibition. In addition, IDO1's substrate profile has always suggested greater promiscuity relative to TDO 44, 45 and the reported flexibility of the enzyme 41 likely contributes to the ability of IDO1 to accommodate a range of structures. We were cognizant of these challenges and opportunities as we explored a new structural derivative of the monoaryl hydroxylamines.
Herein we report our results with regards to these studies.
Results and Discussion

Synthesis of diaryl inhibitors.
The synthesis of the diaryl inhibitors followed the pattern of the previously reported monoaryl hydroxylamines 40 
Enzyme inhibition data analysis.
Analysis of the diaryl compounds with isolated enzyme assays for IDO1, IDO2 and TDO activity allowed a preliminary ranking of the derivatives (Table 1) . These results illustrated an array of activity and selectivity in this class of dioxygenase inhibitors. In all cases, compounds were tested as racemic mixtures, so it is possible that one enantiomer is the preferred and more potent stereoisomer. IDO1, which is the primary focus of most therapeutic work, was most potently inhibited by compounds with bromo and chloro substituents on the aromatic rings (compounds 1-7) with a potency in the range of 1-4 M. This was also consistent with the results from our studies with the monoaryl hydroxylamines 40 . Methoxy or hydroxy substituted derivatives (20, 23, 25) were noticeably less potent (23 M, 85% inhibition and 18% inhibition, respectively). The preference for bromo and chloro substitution on IDO1 inhibitors has also been found with the most potent compounds that have entered the clinic 4 .
In addition to the potency enhancing effects of halogenated derivatives towards IDO1 inhibition, we found two modifications that often led to IDO1 selective inhibitors: 2-fluoro substitution of one aryl ring (10, 12, 13, 16) and diaryl derivatives with a longer chain of atoms between the two aryl rings (5, 11, 17) . In the ortho-fluoro substitution cases, the two most potent examples also have a trifluoromethyl group on the same ring and therefore the highly electron deficient aryl ring may be critical for IDO1 selectivity. With respect to the diaryls with greater distance between the two aryl rings, their selectivity is likely the result of the extended second aryl group better occupying the B pocket of IDO1. Inhibitors that occupy both the A and B pockets of IDO1 often have greater potency 42, 43 , although, to the best of our knowledge, our discovery is the first to illustrate selectivity from an extended binding inhibitor. This could be critical to the development of more selective inhibitors of the dioxygenase family.
New pan, dual and selective dioxygenase inhibitors were also identified ( Fig. 1 
Cell-based data analysis.
The first point that was noticeable in the cell-based IC50 data (Table 2) was that almost all inhibitors demonstrated more potent inhibition than in the isolated enzyme assay. This is quite common with IDO1 screens 46, 47 and seems reasonable to expect for the similarly challenging isolated enzyme assays for TDO and IDO2. In particular, the IDO1 enzyme assay uses a surrogate reduction system (typically methylene blue and ascorbic acid) which is not the native reduction operation, to maintain the IDO1 in its catalytically active ferrous state; for although there is no redox cycling in the catalytic reaction, IDO1 is quite prone to oxidation to the ferric heme in the presence of oxygen. Also, as with the isolated enzyme assays, all compounds were tested as racemic mixtures.
The cell-based and isolated enzyme screens generally demonstrated similar relative potency for IDO1, IDO2 and TDO in most cases, although some differences in selectivity profiles were observed. For example, the same bromo and dichloro substituted derivatives (1-4) that were potent IDO1 inhibitors in the isolated enzyme assay were also potent IDO1 inhibitors in the cellbased assays (0.6-2 M). However, the cell-based data for these compounds exhibited more significant potency with IDO2 and TDO as well. Indeed, most of the diaryl compounds demonstrated pan inhibition with high nanomolar or low micromolar inhibition of all three tryptophan catabolizing enzymes ( Figure 2 ) . In all these cases, the potency for IDO1 was the strongest, albeit in some examples only marginally so or within experimental error. For comparison and as proof of the significant pan inhibitor potency of the diaryl hydroxylamines, two clinical IDO1 inhibitor candidates, epacadostat (INCB24360) and PF-068400003, were tested and are included in Table 2 roughly five-to ten-fold greater potency with IDO1 (~1 M) than either IDO2 (~10 M) or TDO (>20 M). The power of ring halogenation was also witnessed in our previous report 40 on monoaryl O-alkylhydoxylamine derivatives as IDO1 inhibitors.
As with the isolated enzyme assay, the extended binding inhibitor 5 with the greater distance between the two aryl rings demonstrated more than 20-fold selectivity for IDO1 over IDO2 and TDO. However, the other extended binding inhibitors, 11 and 17, were less potent and less selective, illustrating that compound 5 has the better distance between the two aryl rings to generate selective and maximum IDO1 inhibition. Interestingly, there were two compounds, 16
and 21, which showed dual IDO1/TDO inhibitor activity with roughly 10-fold greater potency for IDO1 and TDO (~1-5 M) over IDO2 (~30-50 M). Notably, the loss of the second aryl ring, as in compound 22, resulted in significant attenuation in overall inhibition activity and for TDO in particular. This example serves as an important illustration of the requisite diaryl character in these inhibitors. Surprisingly, the four least potent compounds in the isolated enzyme assay (23) (24) (25) (26) showed single micromolar potency towards IDO1 in the cell-based assay and retained low micromolar inhibition of IDO2 and TDO. Again, this is likely attributed to differences in the isolated enzyme assay procedure versus the cell-based assay. Compound associated cytotoxicity could be a possible complicating factor for interpreting the cell-based enzyme inhibition data and a potential concern with regard to safety and tolerability. Therefore, a viability screen with HeLa cells was undertaken which demonstrated roughly ≥80% viability up to 100 M for all compounds except for 1, 12 and 24
(See Supplementary Data appendix, Figure S3 ). For these three compounds, the cell viability dropped to approximately 60% around 100 M. The overall lack of cytotoxicity apparent at the effective inhibitory dose range for these compounds suggests that general cytotoxicity is not likely to be an issue for advancing the diaryl hydroxylamine series. It was clear that the diaryl hydroxylamines, like the monoaryl hydroxylamines, have little to suggest that they would be problematic. Assessment of impact of human serum protein binding indicated a substantial reduction in inhibitory activity for one of the compounds, 6, while the inhibitory activity of 2 was relatively unaffected (see Supplementary Data appendix, Figure S4 ). This analysis indicates that it should be possible to develop diaryl hydroxylamines inhibitors that are not unduly compromised by serum protein binding.
Conclusions
Several important discoveries were made in the studies reported here. First, diaryl hydroxylamines demonstrated strong potency in isolated enzyme assays and were even stronger in cell-based assays. This reaffirms a common pattern for IDO1 inhibition studies and alerts researchers in the field that isolated enzyme studies should be interpreted with caution. This is understandable because the isolated enzyme assay for these Trp catabolizing enzymes is not an accurate replication of the actual cell environment. Second, the value of halogenation (fluoro, chloro and bromo) to potency in all three enzymes is a critical recognition, echoing the most potent IDO1 inhibitors that have entered the clinic. Third, as seen with 5, extended binding inhibitors do offer selectivity for IDO1 over the two other dioxygenase enzyme targets. Most notably, this study illustrates a rare example of potent pan and IDO1/TDO selective inhibitors.
Although IDO1 inhibitors have been developed and reported for over a decade 26 , the development of pan or variably selective inhibitors is still in its infancy. Indeed, given the recent failure of the IDO1-selective inhibitor epacadostat in the ECHO-301 Phase 3 trial in melanoma, it seems likely that dual or pan inhibitors may be important to the development of effective therapeutic inhibitors of tryptophan catabolism 11 . The illustration in this report that these relatively simple inhibitors have significant potency and unique selectivity is an important development in the field that should benefit other researchers. Future studies will seek to further advance these understandings in the creation of more therapeutically relevant structures.
Experimental Section
General Synthetic Chemistry Experimental Parameters
All reactants and reagents were commercially available and were used without further purification unless otherwise indicated. Anhydrous CH2Cl2 was obtained by distillation from calcium hydride under nitrogen. Anhydrous THF was freshly distilled from Na and benzophenone.
All reactions were carried out under an inert atmosphere of argon or nitrogen unless otherwise indicated. Concentrated refers to the removal of solvent with a rotary evaporator at normal water aspirator pressure followed by further evacuation with a direct-drive rotary vane vacuum pump.
Thin layer chromatography was performed using silica gel 60 Å precoated glass or aluminum m, multiplet; br,broad.
13
C NMR experiments were conducted with the attached proton test (APT) pulse sequence. 13 C multiplicities are reported as δu (up) for methyl and methine, and δd (down) for methylene and quaternary carbons. HPLC was conducted on an Agilent 1100 with an Ascentis Express C-18 column (100 x 4.6 mm, 2.7 m) and a mobile phase of 80:20 MeCN:H2O. GC analyses were performed on the free hydroxylamine with an EI-MS detector fitted with a 30 m x 0.25 mm column filled with cross-linked 5% PH ME siloxane (0.25 µm film thickness); gas pressure 7.63 psi He. Analysis of samples involved heating from 70 to 250°C (10°C/min) and finally holding at 250°C for 7 min. All compounds were found to be >95% purity by elemental analysis or GC as indicated.
General Synthesis of O-Alkyl Hydroxylamines.
To a solution of alcohol (1 mmol) in freshly distilled THF (5 ml) was added triphenylphosphine 
HCl salt formation:
The O-alkyl hydroxylamine was dissolved in a minimal amount of diethyl ether. HCl in anhydrous diethyl ether (1.0 M, 1 eq) was added slowly. The white precipitate was filtered and washed with diethyl ether and dried under high vacuum. 
O-(3-Bromo-α-phenylbenzyl)hydroxylamine hydrochloride (1). Synthesized from 3-bromo-α-
5-(Aminooxy)-5-(3-chlorophenyl)-N-phenylpentanamide hydrochlorie (5).
O-(2-Fluoro-3-trifluoromethyl-α-phenylbenzyl)hydroxylamine hydrochloride (10
O-((2-Fluoro-5-trifluoromethyl-α-phenylbenzyl)hydroxylamine hydrochloride (13).
Synthesized from the respective alcohol according to the general procedure to afford 13 as white crystals in 91% yield. Mp=157-158. (14) . Synthesized from 2,3-dichloro-α-phenyl-benzenemethanol according to the general procedure to afford 14 as white crystals in 63%yield. cDNA were seeded in a 96-well plate at a density of 10,000 cells per well in 100 μL of DMEM + 10% FBS + 1% penicillin-streptomycin and IDO2 expression was induced by the addition of 100 μL of media containing 2 ng/mL doxycycline + 8 mM 5-aminolevulinic acid + 20 μM hemin + 4 mM L-tryptophan. The IDO1 and TDO induction was allowed to proceed for 24 hours, the IDO2 was induced for 48 hours. After induction, the media was discarded, the wells rinsed once, and serial dilutions of compound in 200 μL of appropriate media with the final concentration of tryptophan adjusted to 100 μM for IDO1 and TDO and to 2mM for IDO2. Following incubation at 37 °C for an additional 20 hrs, the assay was stopped by the addition of 50 μL of 50% (w/v)
O-(2,3-Dichloro-α-phenylbenzyl)hydroxylamine hydrochloride
TCA to each well, and the cells were fixed by incubating for 1 hr at 4 °C.
Assessment of IDO1, IDO2 and TDO activity
Compound IC50 values were assessed from single point dilution series with the most potent compounds subsequently retested two or more times and the results reported as averages.
Following the TCA fixation step, the supernatants were transferred to a round-bottomed 96-well plate and incubated at 65 °C for 15 min. The plates were then centrifuged at 1250 × g for 10 min, and 100 μL of clarified supernatant was transferred to a new flat-bottomed 96-well plate and mixed at equal volume with 2% (w/v) p-dimethylaminobenzaldehyde in acetic acid. The yellow reaction was measured at 490 nm using a Synergy HT microtiter plate reader (Bio-Tek, Winooski, VT). Graphs of inhibition curves with IC50 values were generated using Prism v.5.0 (GraphPad Software, Inc.).
Supplementary Data
Full experimental details for the synthesis of alcohols that were not commercially available are described. Copies of 1 H and 13 C NMR spectra for all tested hydroxylamine compounds are also available. Raw IC50 data for top inhibitors in the enzyme and cell-based inhibition assays are shown. Toxicity screen with HeLa cells for diaryl hydroxylamines, epacadostat and PF-0684003 are available. In addition, an assay assessing the impact of human serum protein binding on the apparent IC50 values is also shown. This material is available at …
